Rohit Batta does not open with the molecule. He opens with the emergency room.
“Too often, a patient’s first encounter with ET is a thrombotic event that lands them in the emergency room,” the Alethio Therapeutics chief executive said on 5 November.
That morning the Oxford spin-out announced a $90 million Series A. The round was oversubscribed and co-led by Sofinnova Partners and RA Capital, with founding investor Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford participating.
One asset gets the money. ATX-011 is a monoclonal antibody that binds G6B, a protein displayed on the stem cells that initiate myeloproliferative neoplasms. Alethio wants to eliminate those cells. The drugs patients take today only lower the platelet count they produce.
Essential thrombocythaemia affects more than 140,000 people in the United States, by the company’s estimate. Platelets climb. Clots follow. So can bleeding, bone marrow scarring and transformation to acute myeloid leukaemia.
The ER Visit That Defines the Market
The disease sits in an odd commercial position. It is common enough to support a market Alethio sizes above $1 billion a year in the US alone, and quiet enough that most approved treatments predate the current generation of targeted oncology.
Hydroxyurea, interferon and anagrelide reduce platelet production. None of them separates the cells driving the disease from healthy marrow. Tolerability limits how long patients stay on therapy.
That gap is the opening. Alethio’s founders, Adam Mead and Beth Psaila, spent years mapping which cells seed MPNs. A 2020 single-cell study led by Psaila found that mutant stem and progenitor cells in myelofibrosis were biased toward megakaryocyte production. The paper described early validation of G6B as an immunotherapy target.
G6B Is a Target, Not a Mutation
Most MPN programmes pick a mutation and attack it. JAK2 inhibitors block signalling. CALR programmes chase a mutant chaperone. Alethio went after a surface protein that appears on diseased cells regardless of which mutation started the disease.
G6B is expressed on platelets and megakaryocytes. It also appears on MPN-initiating stem cells and on the megakaryocytes implicated in marrow fibrosis, but not on healthy stem cells. That expression pattern is the entire thesis.
G6B is a highly differentiated target with compelling human data supporting its role in selectively identifying disease-driving cells in MPN.— Maxwell DeNies, RA Capital
Alethio validated the target with its ARTEMIS platform, using samples from more than 100 patients with CALR- or JAK2-mutant MPNs and matched healthy donors. A second programme targets mutant calreticulin, which appears in roughly 30% of MPN patients.
Eighty Percent in Ninety-Six Hours
The preclinical package is small and specific. In two nonhuman primates, platelet counts fell by 80% within 96 hours of dosing and recovered as the antibody cleared. Hemoglobin and white blood cell counts did not move.
ATX-011 is an unconjugated antibody with a modified Fc region. The design reduces unwanted activation while keeping some capacity to clear target cells. In laboratory work selected for an oral presentation at ASH 2026, it did not activate platelets directly, cause aggregation or disrupt megakaryocyte maturation.
Primate platelet response
Two nonhuman primates; counts recovered as the antibody cleared · BioPharm International, 2026
Modelling suggests dosing every three to four weeks could hold normal platelet counts. That schedule has not been tested in humans. The distance between a primate platelet curve and a Phase 1 readout is where first-in-class programmes usually fail.
A Billion-Dollar Market With Old Drugs
Investors have started to reprice the space. In April, Eli Lilly agreed to acquire Ajax Therapeutics, a JAK2 inhibitor developer, for up to $2.3 billion. Oxford Science Enterprises cited that deal as one factor behind its conviction in Alethio.
The competitive map is crowded at the symptomatic end and thin at the disease-modifying end. Incyte’s Jakafi and Takeda’s Mimrylo treat related MPNs. Neither was designed to remove the stem cells that sustain the disease.
| Parameter | Current ET drugs | ATX-011 |
|---|---|---|
| Mechanism | ◐ Lowers platelet production | ✔ Targets G6B on disease-driving cells |
| Mutation dependence | ✗ Indirect, mutation-agnostic by default | ✔ Mutation-agnostic by design |
| Healthy-cell sparing | ✗ Affects healthy marrow | ◐ Preclinical evidence only |
| Clinical stage | ✔ Approved | ✗ IND-enabling |
Company filings and BioPharm International, November 2026
What $90 Million Actually Buys
The round funds ATX-011 through Phase 1/2a and to Phase 3 readiness. Part one of the trial measures safety, exposure-response and proof of mechanism through platelet control. Part two tests depth and durability, with platelet normalisation at Week 12 as the early proof-of-concept readout.
Alethio expects to begin enrolling patients in the first half of 2028, subject to regulators. IND-enabling studies are running now. The first human data is roughly 18 months away.
Where the rest of the pipeline sits
The syndicate is transatlantic and unusually concentrated for a Series A. Sofinnova and RA Capital took board seats. Cancer Research Horizons and the University of Oxford stayed in.
The Moat Is Validation, Not Chemistry
G6B did not arrive from a screening campaign. It came out of single-cell mapping of diseased bone marrow, a technique that only became practical at scale in the past decade.
The 2020 Psaila study compared stem and progenitor cells from patients with myelofibrosis against healthy donors. Mutant clones were skewed toward megakaryocyte production. That skew pointed to a surface marker the diseased cells carried and healthy stem cells did not.
ARTEMIS turned that observation into a validation engine. The platform is built to identify, validate and de-risk mutant drivers and the therapeutic candidates aimed at them. Alethio says it has now checked G6B against samples from more than 100 patients with CALR- or JAK2-mutant MPNs, alongside matched healthy donors.
That kind of work is slow for structural reasons. MPNs progress over years, so patient cohorts accumulate slowly. Bone marrow samples are harder to collect than blood. Antibody programmes need a target that sits on the cell surface, which rules out most of the interesting biology inside the cell.
The result is a moat made of validation rather than chemistry. Any well-run antibody company can build a molecule against a known surface protein. Fewer can show, across a hundred-plus patient samples, that the protein marks the cells worth killing and spares the ones worth keeping.
That distinction explains the investor concentration. Sofinnova and RA Capital are not funding a platform in the abstract. They are funding a target that took years to justify, with a molecule that now has to prove the justification in people.
The Readout That Matters Is Week 12
First-in-class biology carries a specific risk. The primate data show the antibody clears platelets. They do not show that clearing platelets changes the course of ET in people, or that the effect lasts between doses.
Batta frames the goal in patient terms. “The ultimate aim for ATX-011 is to allow patients to go and live their daily lives,” he said.
The trial design reflects that. Platelet normalisation at Week 12 is the early proof of concept. If counts hold there, the programme earns a larger conversation about disease modification. If they do not, the $90 million buys a longer runway and a harder question.
ASH 2026 oral data on platelet activation and megakaryocyte maturation
IND clearance and first-patient enrolment in the first half of 2028
Week 12 platelet normalisation in the Phase 1/2a trial
Whether the G6B antibody-drug conjugate reaches its own IND
Alethio is selling a clean idea: remove the cells, not the mutation. The science supports the first half of that sentence. The second half is still a clinical bet, priced at $90 million and payable at Week 12.